ClinicalTrials.gov
public full text
Public Domain
Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
This placebo-controlled study is designed to determine the efficacy, safety, and tolerability of vortioxetine in the treatment of adults with Major Depressive Disorder (MDD) that is comorbid with Social Anxiety Disorder (SAD). Half of the subjects will be randomized to receive vortioxetine and the other half will receive placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study With Vortioxetine on Emotional Functioning in Patients With Depression#852210
- Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder#967545
- Real-life Effectiveness of Vortioxetine in Depression#1045332
- Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder#810083
- Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults#1125744
Record · ID 1032274
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive